Zimmer Biomet Raised FY23 Adjusted EPS Outlook To $7.47-$7.57 From $7.40-$7.50 (Consensus $7.45); Sees Revenue Growth Of 6.5% - 7% (Prior 5% - 6%)
Portfolio Pulse from Benzinga Newsdesk
Zimmer Biomet has raised its FY23 adjusted EPS outlook to $7.47-$7.57 from $7.40-$7.50, above the consensus of $7.45. The company also expects revenue growth of 6.5% - 7%, up from the previous estimate of 5% - 6%.
August 01, 2023 | 10:58 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Zimmer Biomet's raised EPS outlook and revenue growth expectations for FY23 are likely to positively impact its stock price in the short term.
Zimmer Biomet's raised EPS outlook for FY23, which is above the consensus, indicates that the company is performing better than expected. This, along with the increased revenue growth expectations, is likely to be viewed positively by investors, leading to a potential increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100